IRIS
ALFIERI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.858
EU - Europa 5.493
AS - Asia 2.649
AF - Africa 74
OC - Oceania 4
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.084
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.789
CN - Cina 1.722
IE - Irlanda 1.113
IT - Italia 1.082
FI - Finlandia 1.001
SE - Svezia 913
SG - Singapore 504
DE - Germania 494
UA - Ucraina 471
TR - Turchia 247
FR - Francia 114
IN - India 97
CI - Costa d'Avorio 71
CA - Canada 69
GB - Regno Unito 68
AT - Austria 67
BE - Belgio 62
NL - Olanda 40
CZ - Repubblica Ceca 26
HK - Hong Kong 21
JP - Giappone 17
IR - Iran 15
VN - Vietnam 14
HU - Ungheria 7
RO - Romania 7
PL - Polonia 5
RU - Federazione Russa 5
LU - Lussemburgo 4
AR - Argentina 3
CH - Svizzera 3
DK - Danimarca 3
ES - Italia 3
LT - Lituania 3
NZ - Nuova Zelanda 3
AE - Emirati Arabi Uniti 2
EU - Europa 2
ID - Indonesia 2
KR - Corea 2
PK - Pakistan 2
TW - Taiwan 2
AU - Australia 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
NG - Nigeria 1
PE - Perù 1
PH - Filippine 1
SI - Slovenia 1
ZA - Sudafrica 1
Totale 14.084
Salva come PNG Salva come JPEG
Città #
Dublin 1.111
Chandler 1.054
Jacksonville 560
Ann Arbor 508
Dearborn 397
Parma 379
Singapore 366
Beijing 359
Boardman 320
Ashburn 309
Nanjing 248
Izmir 233
Shanghai 217
Princeton 196
San Mateo 169
New York 157
Bremen 136
Wilmington 115
Nanchang 91
Kunming 88
Shenyang 82
Helsinki 81
Hefei 78
Hebei 74
Jinan 73
Abidjan 71
Chicago 69
Woodbridge 68
Milan 67
Des Moines 66
Vienna 66
Marseille 56
Toronto 55
Los Angeles 49
Pune 45
Brussels 44
Tianjin 44
Jiaxing 42
Seattle 39
Santa Clara 34
Changsha 33
Guangzhou 33
Dallas 30
Houston 30
Munich 30
Modena 28
Norwalk 26
Hangzhou 25
Düsseldorf 24
Amsterdam 23
Redmond 23
Leawood 22
Fremont 20
Bologna 17
Zhengzhou 17
Hong Kong 16
Rome 16
Augusta 15
Brno 15
Dong Ket 14
Fuzhou 13
Neviano degli Arduini 13
Ardabil 12
Monmouth Junction 12
Redwood City 12
Reggio Emilia 12
Wayne 12
Kocaeli 11
Verona 11
Ningbo 10
Taiyuan 10
Auburn Hills 9
Borås 9
Grafing 9
Haikou 9
Lanzhou 9
London 9
Chengdu 8
Leipzig 8
Mumbai 8
Rio Saliceto 8
Binche 7
Leuven 7
Montreal 7
Paris 7
Pavia 7
Rockville 7
Taizhou 7
Xian 7
Auburn 6
Castello Molina di Fiemme 6
Chongqing 6
Follonica 6
Formigine 6
Magdeburg 6
Salsomaggiore Terme 6
Wenzhou 6
Fairfield 5
Florence 5
Frankfurt am Main 5
Totale 9.006
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 207
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 123
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 123
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 123
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 115
Characterization of gefitinib uptake in NSCLC cell lines 106
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 106
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 106
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 105
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 103
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 101
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 99
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 98
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 97
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 96
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 96
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 96
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 95
New MDR1 inhibitors for overcoming multidrug resistance 95
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 94
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 93
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 93
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 93
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 92
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 92
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 90
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 90
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 89
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 89
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 88
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 88
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 88
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 88
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 87
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 86
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 86
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 86
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 86
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 86
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 85
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 85
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 84
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 84
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 84
Antitumoral effect of a nanotechnology-based photodynamic therapy. 84
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 83
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 82
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 81
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 81
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 80
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 80
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 79
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 79
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 78
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 78
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 77
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 77
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 77
An original application of plasma expanders: heart-lung preservation. 77
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 77
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 77
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 77
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 76
Hypertonic stress and amino acid deprivation both increase expression of mRNA for amino acid transport system A 76
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 76
The effect of heat shock on amino acid transport and cell volume in 3T3 cells 75
5-benzylidene-hydantoins as new inhibitors of cell proliferation 75
Attenuata induzione del gene SNAT-2 in fibroblasti umani senescenti esposti a stress iperosmolare 74
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 74
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 74
Stabilization of hsp70 mRNA on prolonged cell exposure to hypertonicity 73
Induzione di osmotolleranza in cellule endoteliali derivate da arteria polmonare 73
Induzione di sistemi di trasporto in condizioni di stress ipertonico 73
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 73
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 73
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 72
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 72
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 72
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 72
Different HSP70 expression and cell survival during adaptive responses of 3T3 and transformed 3T3 to osmotic stress 72
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 72
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 72
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 72
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 72
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 71
Activation of heat-shock transcription factor 1 by hypertonic shock in 3T3 cells 71
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 71
The effect of trehalose on human lung fibroblasts stored in euro-collins and low potassium dextran solutions. 71
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 70
Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration 70
SiO2/SiC core-shell nanowires for nanomedicine applications 70
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 70
Effects of osmolarity, ions and compatible osmolytes on cell-free protein synthesis 69
Irreversible EGFR inhibitor compounds with antiproliferative activity 69
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 69
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 69
Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells 69
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 69
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 68
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 68
Totale 8.447
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.059
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.059
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.679 0 0 0 46 189 306 356 94 224 229 77 158
2020/20211.307 21 131 100 47 162 24 128 53 244 49 287 61
2021/20221.011 44 22 52 65 34 14 135 119 60 71 67 328
2022/20234.244 399 439 279 289 415 470 44 298 1.377 25 169 40
2023/20241.774 86 141 61 64 158 404 130 135 68 88 155 284
2024/2025999 177 283 347 192 0 0 0 0 0 0 0 0
Totale 14.397